Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- 2008
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Charitable contributions to funding cancer services for children and young people in England and Wales
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Jan 2008, In: Journal of Child Health Care. 12, 2, p. 156-168Research output: Contribution to journal › Article › peer-review
- Published
Chiral chromatography: Costs of chiral switching.
Hughes, D. & Hughes, D. A., 1 Jan 2008, In: Pharmaceutical Journal. 281, p. 213Research output: Contribution to journal › Article › peer-review
- Published
Cost-effectiveness considerations in pharmacogenetics.
Hughes, D. & Hughes, D. A., 1 Jan 2008.Research output: Contribution to conference › Paper
- Published
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Effects of the abolition of prescription charges in Wales: a preliminary analysis.
Hughes, D., Cohen, D., Alam, M. F., Hughes, D. A., Dunstan, F. & Routledge, P., 1 Jan 2008, In: International Journal of Pharmacy Practice. 16, Supplement 1, p. A39Research output: Contribution to journal › Article › peer-review
- Published
Integrating compliance and persistence in health economics models
Hughes, D. & Hughes, D. A., 1 Jan 2008.Research output: Contribution to conference › Paper
- Published
Investigating factors influencing user choices to visit either general practioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment.
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness.
Hughes, D., Linck, P. G., Windle, G., Hughes, D. A., Linck, P., Russell, I. T., Morgan, R., Woods, R. T., Burholt, V., Edwards, R. T., Reeves, C. & Yeo, S. T., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Public health interventions to promote well-being in people aged 65 and over: systematic review of effectiveness and cost-effectiveness: Evidence Tables.
Hughes, D., Linck, P. G., Windle, G., Linck, P., Morgan, R., Hughes, D. A., Burholt, V., Reeves, C., Yeo, S. T., Woods, R. T., Edwards, R. T. & Russell, I. T., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Understanding medication compliance and persistence from an economics perspective
Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610Research output: Contribution to journal › Article › peer-review
- Published
Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Feb 2008.Research output: Contribution to conference › Paper
- Published
From efficacy to cost-effectiveness: Impact of patient compliance
Hughes, D. & Hughes, D. A., 1 Feb 2008.Research output: Contribution to conference › Paper
- Published
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Mar 2008Research output: Non-textual form › Web publication/site
- Published
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Mar 2008, In: Value in Health. 11, 2, p. 346Research output: Contribution to journal › Article › peer-review
- Published
The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data
Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.Research output: Contribution to conference › Paper
- Published
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.Research output: Contribution to conference › Paper
- Published
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Apr 2008.Research output: Contribution to conference › Paper
- Published
Effects of the abolition of prescription charges in Wales: A preliminary analysis
Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Apr 2008.Research output: Contribution to conference › Paper
- Published
Costs of non-compliance to antipsychotic medications among patients with schizophrenia.
Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 May 2008.Research output: Contribution to conference › Paper
- Published
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.Research output: Contribution to conference › Paper
- Published
Economic considerations for pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Jun 2008.Research output: Contribution to conference › Paper
- Published
Medicines concordance and game theory.
Hughes, D. & Hughes, D. A., 1 Oct 2008, In: British Journal of Clinical Pharmacology. 66, 4, p. 577Research output: Contribution to journal › Article › peer-review
- Published
Impact of the abolition of the prescription charge in Wales
Hughes, D. & Hughes, D. A., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
Methodological Issues in the literature on costs of non-compliance in chronic diseases.
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008, In: Value in Health. 11, 6, p. A571-A572Research output: Contribution to journal › Article › peer-review
- Published
Methodological issues in the literature on costs of non-compliance in chronic diseases
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
The all wales medicines strategy group: assessments and appraisals
Hughes, D. & Hughes, D. A., 1 Nov 2008.Research output: Contribution to conference › Paper
- Published
Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens
Hughes, D. & Hughes, D. A., 1 Dec 2008, In: British Journal of Clinical Pharmacology. 65, 6, p. 871-878Research output: Contribution to journal › Article › peer-review
- 2009
- Published
A systematic review and empirical analysis of the relation between dose and duration of drug action.
Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.
Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Jan 2009.Research output: Contribution to conference › Paper